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ARTICLE
Maturation of the gut microbiome and risk of
asthma in childhood
Jakob Stokholm1,2, Martin J. Blaser 2, Jonathan Thorsen1, Morten A. Rasmussen1,3,4, Johannes Waage1,
Rebecca K. Vinding1, Ann-Marie M. Schoos1, Asja Kunøe1, Nadia R. Fink1, Bo L. Chawes1, Klaus Bønnelykke1,
Asker D. Brejnrod5, Martin S. Mortensen 5, Waleed Abu Al-Soud5, Søren J. Sørensen5 & Hans Bisgaard1
The composition of the human gut microbiome matures within the ﬁrst years of life. It has
been hypothesized that microbial compositions in this period can cause immune dysregu-
lations and potentially cause asthma. Here we show, by associating gut microbial composi-
tion from 16S rRNA gene amplicon sequencing during the ﬁrst year of life with subsequent
risk of asthma in 690 participants, that 1-year-old children with an immature microbial
composition have an increased risk of asthma at age 5 years. This association is only
apparent among children born to asthmatic mothers, suggesting that lacking microbial sti-
mulation during the ﬁrst year of life can trigger their inherited asthma risk. Conversely,
adequate maturation of the gut microbiome in this period may protect these pre-disposed
children.
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The ﬁrst years of our lives represent a period that is criticalfor susceptibility to environmental exposures. Here, lastingeffects may be introduced to the developing immune sys-
tem through complex host–environment interactions1–3. The
human microbiome contains as many as 1014 bacteria, similar to
the number of cells of an individual4. From birth, humans are
continuously subjected to multiple exposures that inﬂuence
microbiome ecology1,2,5. The composition of the gut microbiome
matures within the ﬁrst years of life6–9 and the microbiome may
have the ability to affect host immune maturation10–12. Pertur-
bation of the microbiome during this critical period of develop-
ment13 may cause asthma, allergy, and other immunologic
disorders14–19. Thus, the microbiome may be an important
environmental factor that determines the transition from health
to disease1,3,20.
The neonatal microbial colonization patterns are greatly
affected by mode of delivery21,22 and use of intrapartum anti-
biotics22,23, factors which may cause long-term microbial
derangements8,9, though the extent of these derangements differs
between studies22,24. Birth by cesarean section is a recognized risk
factor for asthma25,26, as well as for other immune-mediated
diseases in childhood27. Furthermore, antibiotic exposure in the
ﬁrst year of life has also been associated with increased asthma
risk28, again pointing to microbe-mediated mechanisms. Two
studies have associated the gut microbial composition in the ﬁrst
year of life with early wheezy phenotypes19,29 despite relying on
questionnaire-based wheezy phenotypes and omitting microbial
development over time.
The objective of this study is to analyze the nature of gut
colonization patterns during the ﬁrst year of life, and the asso-
ciations of these patterns with the later risk of asthma among
children from the Copenhagen Prospective Studies on Asthma in
Childhood2010 (COPSAC2010) birth cohort. We show that the gut
microbiome, as assessed by β-diversity, relative abundances of
genera and microbial maturation at age 1 year, is associated with
asthma at age 5 years in the 690 children. This effect is only
apparent in children born to asthmatic mothers, and especially
characterizes an asthma phenotype also comprising allergic sen-
sitization. This indicates that the development of the gut micro-
biome during the ﬁrst year of life can impact the development of
childhood asthma, and that adequate microbial maturation in this
period may protect pre-disposed children.
Results
Baseline characteristics of the study cohort. The COPSAC2010
cohort has been followed prospectively with deep clinical phe-
notyping and structured interviews at 11 scheduled visits during
the ﬁrst 5 years of life, with asthma as primary outcome. The
characteristics of the entire cohort of 700 children have been
described in detail30. Of these children, 51% were boys, 57% had
at least one older child in the home at birth, 22% were delivered
by cesarean section, and 46% were treated with antibiotics during
the ﬁrst year of life. The mean maternal age at delivery was 32.2
years and 26% of the mothers had physician-diagnosed asthma.
Microbial composition changes during ﬁrst year of life. The
composition of the gut microbiome changes extensively in early
life, with regard to diversity, complexity, and dominant bacterial
taxa5–9. Therefore, we examined the compositional changes that
occurred in the ﬁrst year of life, before asthma onset. A total of
1696 fecal samples from 690 children arrived in the lab within 24
h of being produced and were characterized by 16S rRNA gene
amplicon sequencing of the V4 region. With a median sequencing
depth of 44,827 reads (interquartile range (IQR): 2358–78,208)
increasing with age of sample, we identiﬁed 3651 unique
operational taxonomic units (OTUs), demonstrating a median
richness of 116 OTUs per sample, with the dominating genera
Bacteroides, Biﬁdobacterium, and Veillonella. Alpha-diversity,
assessed by the Shannon diversity index, was not different
between 1 week (median (IQR), 2.0 (1.5–2.5)) and 1 month (1.9
(1.4–2.5)), but substantially increased at age 1 year (2.8 (2.4–3.3)),
(P< 0.001). Similarly, the Chao1 index showed a minor decrease
between 1 week (131 (96–175)) and 1 month (121 (78–168)) (P<
0.001) and a substantial increase at age 1 year (295 (203–366)) (P
< 0.001). Although signiﬁcant differences in the population
structure (β-diversity), as determined by weighted UniFrac dis-
tances, were found between ages 1 week and 1 month (F = 26.5,
R2 = 2.4%, P< 0.001), the greatest change in structure was
between ages 1 month and 1 year (F = 558.5, R2 = 33.2%, P<
0.001, Fig. 1a). To evaluate which bacterial genera were involved
in these observed temporal differences in α- and β-diversity, we
examined the relative abundances of the most prevalent taxa.
Each of the 20 most abundant genera changed signiﬁcantly in
relative abundance during the ﬁrst year of life (Kruskal–Wallis
test, all P-values< 0.01) with the largest differences observed
from age 1 month to 1 year (Supplementary Fig. 1).
Microbial community types and maturation are age-
determined. To further describe the compositional differences
in the microbial populations, we applied a clustering method
(Partitioning around medoids (PAM) clustering)31,32 to separate
all the fecal samples by their weighted UniFrac distances taking
microbial phylogeny and abundances into account, but without
including the time point in the computational model (Fig. 1b).
This approach divided the samples into two distinct microbial
community types (PAM clusters) (silhouette width, 0.30), largely
representing the child’s age at sampling, with PAM cluster 1 (N =
1019) mainly composed of the 1-week and 1-month samples and
PAM cluster 2 (N = 677) chieﬂy composed of the 1-year samples
(Fig. 1c). The ﬁve most discriminating indicator OTUs for each
cluster were identiﬁed for PAM cluster 1 as Enterobacteriaceae,
Staphylococcus, Streptococcus, Biﬁdobacterium and Enterococcus,
and for PAM cluster 2 as Faecalibacterium, Bacteroides(x3), and
Anaerostipes. Using the Shannon diversity index, we identiﬁed
higher α-diversity, as well as a microbiome dominated by
the phylum Bacteroidetes in PAM cluster 2 compared to PAM
cluster 1, which was dominated by Proteobacteria (Supplemen-
tary Fig. 2). As such, these PAM clusters likely represent the age-
related maturation of the intestinal microbial populations7,33,34.
To determine whether the PAM cluster transition at age 1 year
was dependent on environmental factors, a wide range of expo-
sures (including delivery method and antibiotics in the ﬁrst year
of life) were examined. Among these, only the presence of older
children in the home from birth was signiﬁcantly associated with
the clusters; of the 34 children with a PAM cluster 1 composition
at age 1 year, only 24% (N = 8) had older children in the home
compared to 57% (N = 334) of the 589 children in PAM cluster 2
(χ2 test P< 0.001). The microbial populations by means of β-
diversity at age 1 month was not associated with PAM cluster at
age 1 year.
To further explore the microbial maturation process over time,
we calculated microbiota-by-age z-scores (MAZ)7 for all samples.
The model is trained from the microbial composition on a data
set with known sample age, and afterward predicts the microbial
age for each sample based solely on the microbial composition.
Microbiota age increased signiﬁcantly for each adjacent time
point (Wilcoxon test, P-values< 0.001) (Supplementary Fig. 3).
Microbial population structure associates with later asthma.
Next, we sought to examine whether associations existed between
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the overall microbial composition at the different time points and
the later development of asthma. Current asthma at age 5 years
was used as the primary end-point, as it represents a strong
persistent clinical phenotype; many children experience episodes
of asthma-like symptoms in the ﬁrst years of life, but outgrow
their asthma symptoms before school-age35. Among the 648
children with follow-up to age 5 years, the prevalence of ongoing
asthma at age 5 was 9% (N = 60). There were no signiﬁcant
associations between α-diversity (Shannon diversity and Chao1
indices) at any time point and asthma risk, also after adjustment
for potential confounders (older siblings, duration of exclusive
breastfeeding, hospitalization after birth, antibiotic use, and
delivery mode). There were no signiﬁcant associations between β-
diversity at the two earliest time points; however, the microbial
populations were signiﬁcantly different at 1 year in children who
had asthma at age 5 compared to non-asthmatics (F = 3.4, R2 =
0.6%, P = 0.003). To further explore this ﬁnding, we stratiﬁed the
samples at age 1 year according to maternal asthma status. The
microbiome-asthma association was found only in the 147 chil-
dren born to asthmatic mothers (F = 6.3, R2 = 4.2%, P< 0.001)
but not in children of non-asthmatic mothers (F = 0.7, R2 = 0.2%,
P = 0.65), demonstrating a signiﬁcant interaction (P = 0.003)
(Fig. 2). In a test of sensitivity, we adjusted these analyses for
potential confounders (older siblings, duration of exclusive
breastfeeding, hospitalization after birth, antibiotic use, and
delivery mode). The signiﬁcance levels remained essentially
unchanged (All children: F = 3.5, R2 = 0.6%, P< 0.001; asthmatic
mother: F = 6.2, R2 = 4.1%, P< 0.001; non-asthmatic mother: F =
0.7, R2 = 0.2%, P = 0.647). There were no differences in relation to
asthmatic status of the father. Neither maternal nor paternal
asthma status was associated with the α- or β-diversity at any
time point (maternal asthma vs. β-diversity: Supplementary
Fig. 4). However, that the microbial composition was not affected
by maternal asthma status suggests that only susceptible children,
exposed to inappropriate microbial stimulation during the ﬁrst
year of life, may express their inherited asthma risk. In a test of
sensitivity, we also examined associations between population
structure at age 1 year in children born by asthmatic mothers and
asthma risk using other β-diversity indices that are not biased by
the dominant taxa (unweighted UniFrac and Jensen–Shannon
divergence), which yielded similar results (P< 0.001).
Relative abundance at age 1 year associates with later asthma.
To understand whether the later asthma risk was affected by
speciﬁc bacterial genera present earlier, we examined the relative
abundances of the most common genera. For the 20 most
abundant genera present in the 1-year samples, we observed
increased risk of asthma at age 5 years associated with higher
abundance of Veillonella (asthma vs. non-asthma; median relative
abundance, 0.94 vs. 0.29%; Wilcoxon rank-sum test, P = 0.035)
and with lower abundance of Roseburia (0.27 vs. 0.66%; P =
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Fig. 1 Microbial compositions change in the gut over the ﬁrst year of life. PCoA plots of weighted UniFrac distances. a Separation of the composition by
sampling time point. b Separation of the bacterial populations by Partitioning around medoids (PAM) clusters (optimal number of clusters is 2; silhouette
width= 0.30). The ﬁve most distinctive indicator OTUs for each of the two clusters were: PAM cluster 1 (N= 1019): Enterobacteriaceae, Staphylococcus,
Streptococcus, Biﬁdobacterium and Enterococcus, and PAM cluster 2 (N= 677): Faecalibacterium, Bacteroides(x3), and Anaerostipes. Ellipses demonstrate the
mean± 2 SD in a and b. c Relationship between sampling time point and PAM cluster
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0.042), Alistipes (0.04 vs. 0.35%; P = 0.002), and Flavonifractor
(0.05 vs. 0.07%; P = 0.002). If the child was born to an asthmatic
mother, 8 of these 20 genera were signiﬁcantly associated with
their development of asthma, whereas there were no signiﬁcant
associations if the mother did not have asthma (Fig. 3). In chil-
dren born to asthmatic mothers, asthma at age 5 years was
negatively associated with relative abundance in the age 1-year
sample of the genera Faecalibacterium (0.59 vs. 3.27%; P = 0.010),
Biﬁdobacterium (0.47 vs. 2.27%; P = 0.006), Roseburia (0.01 vs.
0.76%; P< 0.001), Alistipes (0.01 vs. 0.39%; P = 0.003), Lachnos-
piraceae incertae sedis (0.05 vs. 0.19%; P = 0.018), Ruminococcus
(<0.01 vs. 0.13%; P = 0.004) and Dialister (<0.01 vs. 0.15%; P =
0.007) and positively correlated only with Veillonella (1.41 vs.
0.23%; P = 0.039) (Fig. 3). The genera that were found in lower
abundances at age 1 year among children who later became
asthmatics have been considered as determinants of a healthy
mature gut composition36. The majority of these genera were
highly correlated at 1 year, while being negatively correlated with
the genus Veillonella (Supplementary Fig. 5). None of the 20 most
abundant genera at 1 week or 1 month were associated with
asthma development. To further examine the associations
between the microbial composition at age 1 year and asthma at
age 5 in children born to asthmatic mothers, a cross-validated
sparse PLS model was constructed to identify jointly contributing
taxa at age 1 year that would predict later asthma in these chil-
dren. This resulted in a one-component model based on the
relative abundances of 60 genera (Supplementary Fig. 6). The
model demonstrated a high predictive capacity for asthma (cross-
validated AUC 0.76) and the many contributing taxa suggest a
global delayed microbial maturation at age 1 year in children with
asthma at age 5.
Community types at age 1 year associates with later asthma. To
formally test whether the maturation of the microbiome was a
determinant for asthma development, we used our microbial
community types (PAM clusters) as indicators of micro-
bial maturation. After excluding children without full 5-year
follow-up, transient asthma and diagnosis before the 1-year
sample (N = 105), the risk of developing persistent asthma if the
child’s microbiome remained in PAM cluster 1 at 1 year of age
(N = 28) was compared to children with transition to PAM cluster
2 (N = 490), and all analyses were adjusted for the presence of
older children (Fig. 4). During the ﬁrst 5 years of life, the risk of
developing persistent asthma was increased (adjusted hazard ratio
(aHR) 2.87 (1.25−6.55), P = 0.013) if the microbiome remained in
PAM cluster 1 at age 1. This effect was driven solely by the 120
children born to asthmatic mothers (PAM1, N = 7 vs. PAM2, N =
113) (aHR 12.99 (4.17−40.51), P< 0.001), whereas there was no
microbial effect on asthma development for the 398 children of
non-asthmatic mothers (PAM1, N = 21 vs. PAM2, N = 377) (aHR
0.56 (0.07−4.16), P = 0.57), demonstrating signiﬁcant interaction,
P = 0.011. In a test of sensitivity, we adjusted these analyses fur-
ther by including other potential confounders (older siblings,
duration of exclusive breastfeeding, hospitalization after birth,
antibiotic use, and delivery mode). All estimates and signiﬁcance
levels remained essentially unchanged (all children: aHR 2.91
(1.25−6.79), P = 0.013; asthmatic mother: aHR 10.92 (3.44
−34.67), P< 0.001; non-asthmatic mother: aHR 0.56 (0.07−4.23),
P = 0.572). We found no associations of PAM clusters with the
transient asthma phenotype. These analyses provide further evi-
dence that having the more immature gut microbial composition
at age 1 year may be a trigger for asthma development in sus-
ceptible children.
Low 1-year microbial maturity associates with later asthma. We
then applied another validated method for determining the early
life maturation of the intestinal microbial populations using the
MAZ score. The microbial maturity (predicted microbiota age
−median microbiota age) and MAZ (microbial maturity/SD) were
used as metrics7,33,34. We sought to determine whether a lower
MAZ score at age 1 year was associated with later asthma. During
the ﬁrst 5 years of life, the risk of developing persistent asthma
was increased with low maturity (below median) in MAZ at
1 year (low maturity, N = 257 vs. high maturity, N = 261) (HR
1.77 (1.02−3.07), P = 0.043). Low microbial maturity was only
associated with later asthma in children born to asthmatic
mothers (low maturity, N = 63 vs. high maturity, N = 57) (HR
6.53 (1.93−22.06), P = 0.003), and not in children of non-
asthmatic mothers (low maturity, N = 194 vs. high maturity, N
= 204) (HR 0.92 (0.46−1.84), P = 0.81), demonstrating signiﬁcant
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Fig. 2 β-diversity in the 1-year fecal samples associates with later asthma. PCoA plots of weighted UniFrac distances. Microbial compositions are assessed
in relation to a child’s asthma status at age 5 years, and stratiﬁed by maternal asthma. P-values correspond to Adonis PERMANOVA tests. Ellipses
demonstrate the mean± 1 SD of children, who at age 5 years were asthmatic (orange) (N= 58) or non-asthmatic (green) (N= 531). Subsets include:
asthmatic mother, asthmatic (orange) (N= 25), and non-asthmatic (green) (N= 122); non-asthmatic mother, asthmatic (orange) (N= 33), and non-
asthmatic (green) (N= 409)
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interaction, P = 0.006 (Supplementary Fig. 7). In total, adequate
maturation of the gut microbiome in this period appears critical
for healthy (non-asthmatic) development and may protect chil-
dren with pre-dispositions.
Low microbial maturity associates with number of asthma-like
episodes. We then examined a secondary asthmatic end-point,
the total number of asthma-like episodes in the ﬁrst 3 years of life,
which is a marker of disease burden. Children with microbiome
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Fig. 4 Kaplan–Meier plots illustrate risk of asthma in the ﬁrst 5 years of life according to Partitioning Around Medoids (PAM) cluster at 1 year.
Comparisons shown of all children and stratiﬁed by maternal asthma, demonstrating interaction between PAM cluster and maternal asthma (P= 0.01).
Associations are quantiﬁed by Cox proportional hazards regression, adjusted for presence of older children in the home (aHR, adjusted Hazard Ratio).
Children with a transient asthmatic phenotype (remission before age 5 years) are excluded. Curves are colored according to cluster; All: PAM cluster 1
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composition in PAM cluster 1 at 1 year experienced more epi-
sodes of troublesome lung symptoms compared with PAM cluster
2 (median (IQR); PAM1 vs. PAM2, 6 (4–18) vs. 5 (2–10); inci-
dence risk ratio (IRR) 1.54 (1.12–2.12), P = 0.008). This was more
pronounced in children born to asthmatic mothers (interaction P
= 0.040, median (IQR); PAM1 vs. PAM2, 19 (12–27) vs. 6 (3–12);
IRR 2.35 (1.48-3.74), P< 0.001). Likewise, lower microbial
maturity as assessed by MAZ score at age 1 year was associated
with more episodes (IRR 1.13 (1.06–1.20), P< 0.001), again with
an enhanced effect in children of asthmatic mothers IRR 1.26
(1.05–2.91), P = 0.016. Thus, consistent with the ﬁndings for
asthma development, low maturity of the microbiome at age
1 year was also associated with more asthma-like episodes.
The associations remain robust at higher sequencing depth. To
test the robustness of these ﬁndings, the analyses were stratiﬁed
by sequencing depth to only include samples with more than
10,000 reads. The PAM clustering, MAZ, and association results
with asthma and episodes of troublesome lung symptoms all were
robust with reference to this more stringent inclusion criterion.
Furthermore, we found no signiﬁcant differences in sequencing
depth at 1 year between children, who did or did not develop
asthma (median (IQR); asthma vs. non-asthma, 54,260
(12,018–74,971) vs. 51,940 (12,010–73,050), P = 0.8); adjustment
of the results for sequencing depth resulted in essentially no
difference.
Microbial populations describe asthma with sensitization. To
explore whether the results were characterizing a speciﬁc asth-
matic phenotype, the children were further subdivided by allergic
sensitization in childhood. The microbial populations by
means of β-diversity at age 1 year were signiﬁcantly different
whether the child had asthma or not with or without sensitization
(four categories of comparison) (F = 1.7, R2 = 0.9%, P = 0.020).
Again, this was mainly apparent among children born to asth-
matic mothers (F = 2.9, R2 = 5.9%, P< 0.001) with no signiﬁcant
effects among children born to non-asthmatic mothers F = 0.7,
R2 = 0.5%, (P = 0.887). Especially, the phenotype of asthma with
allergic sensitization was associated with skewed β-diversity
(Fig. 5).
Discussion
With the primary objective of making accurate asthma diagnoses
and comprehensive phenotyping, we found that the gut micro-
biome at age 1 year was associated with asthma at age 5 in a
prospective cohort of 700 children. Parallel observations were
apparent for overall β-diversity, relative abundances of genera,
and maturation by means of PAM clustering and MAZ. The
effect was only apparent in children born to asthmatic mothers,
but the composition and maturation of the gut microbiome in
early life was not affected by maternal asthma status. Because of
the observational design of the study, we cannot unravel causality
or directionality, but our ﬁndings indicate that children born to
asthmatic mothers harbor a susceptibility to inﬂuences from the
gut microbiome and that adequate maturation in this period may
protect these pre-disposed children.
The main study strength is the design of the COPSAC2010 birth
cohort, which is a replication and extension of the COPSAC2000
cohort37 with regular longitudinal clinical follow-up, meticulous
daily symptom recording, and acute care visits to the clinical
research site, which has a long record of performing clinical
follow-up in cohort studies30,37. All diagnoses and treatments of
asthma were performed solely by COPSAC physicians30. This
ensured highly speciﬁc end-points and accurate assessment of
time of disease onset. Importantly, this allowed for discrimination
between persistent and transient asthma phenotypes. Asthma at
age 5 years is a robust phenotype compared with wheezing in the
ﬁrst few years of life, which for most children merely describes a
transient phenotype, especially when accompanied by increased
early life severity and sensitization35,38,39. Collecting fecal samples
longitudinally from age 1 week allowed for description of the
development of the microbial populations during the ﬁrst year of
life.
Our study is by design observational, which limits assessment
of causal relationships. However, the number of participants
allows for stratiﬁcation of the data by physician-diagnosed
P = 0.020
−0.1
0.0
0.1
0.2
−0.1 0.0 0.1 0.2
PC
2 
(16
.4%
)
All (n=581)
P < 0.001
−0.1 0.0 0.1 0.2
PC1 (42.2%)
Asthmatic mother (n=142)
P = 0.887
−0.1 0.0 0.1 0.2
Non asthmatic mother (n=439)
Asthma, sensitized Asthma, not sensitized No asthma, sensitized No asthma, not sensitized
Fig. 5 β-diversity at 1 year associates with asthma and allergic sensitization. PCoA plots of weighted UniFrac distances. Microbial compositions are
assessed in relation to a child’s asthma status at age 5 years and allergic sensitization before age 18 months, and stratiﬁed by maternal asthma. P-values
correspond to Adonis PERMANOVA tests. Ellipses demonstrate the mean± 1 SD of children, who at age 5 years were: asthmatic and sensitized (red) (N=
12), asthmatic and not sensitized (purple) (N= 45), non-asthmatic and sensitized (blue) (N= 59), or non-asthmatic and not sensitized (green) (N= 465).
Subsets include: asthmatic mother, asthmatic and sensitized (red) (N= 5), asthmatic and not sensitized (purple) (N= 19), non-asthmatic and sensitized
(blue) (N= 15), and non-asthmatic and not sensitized (green) (N= 103); non-asthmatic mother: asthmatic and sensitized (red) (N= 7), asthmatic and not
sensitized (purple) (N= 26), non-asthmatic and sensitized (blue) (N= 44), and non-asthmatic and not sensitized (green) (N= 362)
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maternal asthma, which suggests potential mechanisms. Our
observation also provides an initial indication of which children
might beneﬁt from microbial manipulation in the ﬁrst year of life.
Although the 16S rRNA gene amplicon sequencing technique
provides a thorough description of the overall microbial popu-
lations, with sequencing of only the V4 region, the method only
allows for robust classiﬁcation of the individual taxa at the genus
level. This limits our interpretation of the results, as we cannot
describe the direct effect of speciﬁc species or strains. Further-
more, we cannot rule out that other gut microbiome components,
which have not been characterized in the study (e.g., gut viral
and/or fungal colonization), could be partly or fully responsible
for some of the observed effects.
Our results suggest that the development of persistent asthma
in childhood may be mediated through a skewed maturation of
the gut microbiome in the ﬁrst year of life, predominantly in
children born to asthmatic mothers. Since the hygiene hypothesis
was ﬁrst described40, multiple studies have linked indirect puta-
tive causes of microbial alterations in the ﬁrst years of life with
later risk of immune-mediated diseases3. Laboratory models have
also provided proof of the microbiomeʼs ability to modulate
immune functions of the host2,13,41. Delivery mode has been
studied intensively and the associations of cesarean section-birth
with asthma25,26 and other chronic childhood disorders27 have
been largely consistent. Furthermore, delivery by cesarean section
greatly inﬂuences the earliest microbiome and its develop-
ment5,21,22,42. Antibiotics in the ﬁrst year of life have also been
conﬁrmed both to perturb the gut microbiome8,9 as well as being
associated with asthma risk28. However, these only represent
indirect associations between microbial alterations and later dis-
ease risk, whereas we show direct and robust associations between
the overall β-diversity, taxon relative abundances, and microbial
maturation and risk of asthma at age 5.
Of the 20 most abundant genera in the samples of the children at
age 1 year, we reported eight associated with asthma at age 5 in
children born to asthmatic mothers. The most abundant Firmicutes
families in the healthy adult human gut are Lachnospiraceae
(including Lachnospiraceae incertae sedis and Roseburia) and
Ruminococcaceae (including Ruminococcus and Faecalibacterium)36.
The lower relative abundances of these genera in children who later
become asthmatic could indicate overall delayed microbial matura-
tion7. A study19 from the Canadian Healthy Infant Longitudinal
Development (CHILD) cohort identiﬁed associations between lower
Faecalibacterium and Lachnospira at age 3months and an early
allergic wheezy phenotype at age 1 year, consistent with our ﬁndings.
However, opposite to our study, they identiﬁed Veillonella as being
protective. This dichotomy could be explained by differences in the
disease phenotypes studied, since early life wheeze is a hetero-
geneous group35 not directly comparable with the 5-year asthma
phenotype we studied. However, the protective association of
Veillonella in the CHILD study was not apparent in the 1-year
samples, which is similar to our ﬁndings. In the genus Faecali-
bacterium, the only known species is F. prausnitzii, which is a
butyrate-producing bacterium, considered to have anti-
inﬂammatory activities43. Conversely, lack of F. prausnitzii is a
marker for inﬂammatory bowel disease44, obesity, and diabetes.
We found Faecalibacterium as the most speciﬁc indicator for the
more mature PAM cluster 2 and in lower abundance among
children who later became asthmatic. This, and the association
with the age-related microbiota score (MAZ), are consistent with
a potential causal role, and could suggest a mechanism of delayed
maturity inﬂuencing immune development in susceptible chil-
dren. For decades, Biﬁdobacterium has been recognized as a
potential protector against allergic disease45 and lack of Rumi-
nococcus in earliest life has also been associated with allergic
sensitization46. The lack of association between bacterial taxa at
1 week and 1 month and later asthma points toward microbial
alterations going on between 1 month and 1 year. A deviation
might have been observed already at 3 months as suggested in the
CHILD study19. Furthermore, a skewed microbial composition at
age 1 year was mainly associated with an allergic asthmatic
phenotype, which is also in line with ﬁndings from the CHILD
study19. The univariate genus-level relative abundance results
were further expanded in a multivariate supervised model, again
pointing toward differences in the entire bacterial community
structure. For children born to asthmatic mothers, we demon-
strated a cross-validated AUC of 0.76 for predicting asthma at age
5 years from the microbial composition at 1 year. In comparison,
a large study using genetic risk scores of the highest-ranked
asthma risk alleles demonstrated an AUC of 0.54–0.57 for pre-
diction of school-age asthma, and an AUC of 0.59 for preschool
persistent wheeze47.
Maternal asthma status did not affect the microbial popula-
tions of the children and therefore did not confound our results.
Maternal asthma was however, a key effect modiﬁer between the
microbiome and asthma risk in our study, which points to sus-
ceptibility to host–microbial interactions speciﬁcally for these
children. Such susceptibility could arise from an inborn immune
deviation determined by maternal asthma status, as we have
reported in this cohort48. Stronger heritability of maternal over
paternal asthma has been described49, consistent with our ﬁnd-
ings, which points towards mechanisms beyond strict genetic
effects.
Our results suggest that the lack of maturation of the gut
microbiome in the ﬁrst year of life is the critical determinant for
increased asthma risk as illustrated by the microbial community
type analyses. Having older siblings was the only signiﬁcant
determinant for belonging in the more mature PAM cluster 2 at
age 1 year, and is consistent with a microbial mechanism for the
original hygiene hypothesis40. We speculate that microbial
transfer from the older child may advance maturation of the gut
composition and, through appropriate stimulation of the devel-
oping immune system, cause protection from asthma in otherwise
susceptible children.
Probiotic intervention trials in pregnancy and in early life have
so far failed to prove effective in reducing asthma risk50. How-
ever, this could be due to species selection or inadequate (single
or few species) compositions of the probiotics. It can be specu-
lated that the global microbial population and delayed maturation
in the ﬁrst year of life matters more than individual taxa. Our
results suggest possible beneﬁcial effects of at least seven of the
most abundant genera among the children born to asthmatic
mothers. Because our results are observational and most of the
taxa associated with lower asthma risk demonstrate collinearity,
we are not able to pinpoint speciﬁc causal taxa; however, the
multivariate model illustrates many jointly contributing taxa and
not a single risk taxon, consistent with a global effect of the
microbiota. Therefore, contributing bacterial strains must be
identiﬁed, potential mechanisms validated, and immunological
features determined in future experimental models. We speculate
that a mixture of the strains to be identiﬁed could form the basis
for a next-generation probiotic that could be tested in a rando-
mized controlled trial to children at risk.
Our results suggest that the maturation of the gut microbiome
during the ﬁrst year of life has an important role in the devel-
opment of childhood asthma, especially in children born to
asthmatic mothers, and that older children in the home may help
advance the maturation. Our results suggest potential beneﬁcial
effects of speciﬁc microbial supplementation in the ﬁrst year of
life for children at high risk for developing asthma.
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Methods
Ethics statement. The study was conducted in accordance with the guiding
principles of the Declaration of Helsinki and was approved by The National
Committee on Health Research Ethics (H-B-2008-093) and the Danish Data
Protection Agency (2015-41-3696). Both parents gave written informed consent
before enrollment.
Study population. The COPSAC2010 cohort is a population-based birth cohort of
700 children recruited in pregnancy and has been followed prospectively at the
COPSAC research unit with deep clinical phenotyping at 11 scheduled visits during
the ﬁrst 5 years of life. Of these 690 had a fecal sample characterized. The study
pediatricians collected all information during these clinical visits scheduled at
1 week, 1, 3, 6, 12, 18, 24, 30, and 36 months, and yearly thereafter. Additional
acute care visits were arranged whenever the children experienced lung or skin
symptoms30. The symptom burden between visits was captured with daily diary
cards monitoring: signiﬁcant troublesome lung symptoms including components
of cough, wheeze, and dyspnea; skin symptoms; and respiratory infections. The
study pediatricians were the only physicians responsible for diagnosis and treat-
ment of asthma, allergy, and eczema adhering to predeﬁned algorithms30.
Primary end-point. Asthma was diagnosed based on a previously detailed quan-
titative symptom algorithm requiring all of the following criteria51–53: (1) veriﬁed
diary recordings of ﬁve episodes of troublesome lung symptoms within 6 months,
each lasting at least 3 consecutive days; (2) symptoms typical of asthma including
exercise-induced symptoms, prolonged nocturnal cough, and/or persistent cough
outside of common colds; (3) need for intermittent rescue use of inhaled β2-
agonist; and (4) response to a 3-month course of inhaled corticosteroids and
relapse upon ending treatment51. Remission was deﬁned by 12 months without
relapse upon cessation of inhaled corticosteroid treatment. For analyses, we used
the cross-sectional ongoing asthma diagnosis at age 5 years and the time to disease
onset of either transient or persistent asthma (ongoing diagnosis at age 5 years).
Secondary end-point. Episodes of troublesome lung symptoms included the
number of episodes lasting three or more consecutive days in the ﬁrst 3 years of
life, with symptoms including cough, wheeze, and/or dyspnea severely affecting the
well-being of the child.
Covariates. Information on physician-diagnosed asthma in the mother and father
(yes/no), maternal age at birth, smoking during pregnancy (yes/no), education (3
levels), household income (3 levels), antibiotics in pregnancy (yes/no, for any
treatment), preeclampsia (yes/no), gestational diabetes (yes/no), delivery type
(three levels: vaginal delivery, emergency cesarean section, or elective cesarean
section), gestational age, hospitalization of the child after birth (yes/no), antibiotics
to the child (yes/no, for any treatment before age 1 year), household pets (yes/no,
for cat and/or dog), older children in the home (yes/no), and duration of exclusive
and total breastfeeding period was obtained during the scheduled visits to the
COPSAC clinic. Information on intrapartum antibiotics and antibiotic use during
pregnancy and childhood was validated against national registries54.
Allergic sensitization was determined at 6 and 18 months of age as any skin
prick test (SPT) ≥2 mm (ALK-Abello, Horsholm, Denmark) and by speciﬁc IgE
(sIgE) ≥0.35 kUa/L against milk, egg, dog, or cat (ImmunoCAP; Thermo Fischer
Scientiﬁc, Allerod, Denmark)30. Children classiﬁed as “not sensitized” were both
SPT and speciﬁc IgE negative for all tested allergens.
Sample collection. Fecal samples were collected 1 week, 1 month, and 1 year after
birth, either at the research clinic or by the parents at home using detailed
instructions. Each sample was mixed on arrival with 1 mL of 10% vol/vol glycerol
broth (Statens Serum Institut, Copenhagen, Denmark) and frozen at −80 °C.
DNA extraction. Genomic DNA was extracted from the infants’ samples using the
PowerMag® Soil DNA Isolation Kit optimized for epMotion® (MO-BIO Labora-
tories, Inc., Carlsberg, CA, USA) using the epMotion® robotic platform model 5075
(Eppendorf) according to the manufacturer’s protocol with the following altera-
tions to the workﬂow: 150–250 µL of the samples were added to the 96-well bead
plate containing 750 µL bead/RNase A Solution and 60 µL lysis solution. Cen-
trifugation steps were performed at 3220xRCF for 9min. Removal of enzymatic
inhibitors and DNA puriﬁcation was performed as described by the manufacturer.
Finally, the DNA was eluted with 100 µL Tris buffer (10 mM, pH 7.5). DNA
concentrations were determined using the Quant-iT™ PicoGreen® quantiﬁcation
system (Life Technologies, CA, USA). Extracted DNA was stored at −20 °C.
16S gene amplicon sequencing. The 16S rRNA gene ampliﬁcation procedure was
divided into two PCR steps. In the ﬁrst PCR reaction, the hypervariable V4 region
of the 16S rRNA gene was ampliﬁed using the modiﬁed broad range primers 515F
(5′-GTGCCAGCMGCCGCGGTAA-3′) and 806R (5′-GGAC-
TACHVGGGTWTCTAAT-3′)55–57. Ampliﬁcation was performed in 96-well
microtiter plates with a reaction mixture consisting of 1× AccuPrime PCR Buffer
II, 0.6 U AccuPrime Taq DNA Polymerase (Invitrogen, Life technologies, CA,
USA), 0.5 µM primer 515 F, 0.5 µM primer 806 R, and 2 µL template DNA, giving a
total volume of 20 µL per sample. Reactions were run in a 2720 thermal cycler
(Applied Biosystems®, Life Technologies, CA, USA) according to the following
cycling program: 2 min of denaturation at 94 °C, followed by 30 cycles of 20 s at
94 °C (denaturing), 30 s at 56 °C (annealing), and 40 s at 68 °C (elongation), with a
ﬁnal extension at 68 °C for 5 min. For each plate, a negative template-free control
and a positive control containing 2 µL DNA from a known bacterial mock com-
munity (1 ng/µL; HM-782D, BEI Resources, VA, USA) were included. The PCR
products were quantiﬁed using the Quant-iT™ PicoGreen® quantiﬁcation system
(Life Technologies) and samples with a concentration above 6 ng/µL were diluted
to ~3–6 ng/µL prior to further analysis.
Sequencing primers and adaptors were added to the amplicon products in the
second PCR step as follows: 2 µL of the diluted amplicons were mixed with a
reaction solution consisting of 1× AccuPrime PCR Buffer II, 0.6 U AccuPrime Taq
DNA Polymerase (Invitrogen, Life Technologies) and 0.5 µM fusion forward and
0.5 µM fusion reverse primer (total volume 20 µL). The PCR was run according to
the cycling program above except with a reduced cycling number of 15. The
ampliﬁcation products were puriﬁed with Agencourt AMPure XP Beads (Beckman
Coulter Genomics, MA, USA) according to the manufacturer’s speciﬁcations using
0.7× volume beads and quantiﬁed as described above. Equimolar amounts of the
ampliﬁcation products were pooled together in a single tube. The pooled DNA
samples were concentrated using the DNA Clean & Concentrator™−5 Kit (Zymo
Research, Irvine, CA, USA) according to the manufacturer’s instructions. The
concentration of the pooled libraries was determined using the Quant-iT™ High-
Sensitivity DNA Assay Kit (Life Technologies) following the speciﬁcations of the
manufacturer. Amplicon sequencing was performed on the Illuimina MiSeq
System (Illumina Inc., CA, USA). For each run, a 1.0% PhiX internal control was
included. All reagents used were from the MiSeq Reagent Kits v2 (Illumina Inc.).
Automated cluster generation and 2 × 250 bp paired-end sequencing with dual-
index reads were performed. The sequencing output was generated as
demultiplexed fastq-ﬁles for downstream analysis. Up to 192 samples were
sequenced per run.
Data processing. Fastq-ﬁles demultiplexed by the MiSeq Controller Software
(Illumina Inc.) were trimmed for ampliﬁcation primers, diversity spacers, and
sequencing adapters using biopieces (www.biopieces.org), mate-paired and quality
ﬁltered (USEARCH v7.0.1090)58. UPARSE59,60 was used for OTU clustering as
recommended, in particular removing singletons after dereplication. Chimera
checking was performed with UCHIME61 against Mothurs supplied version of the
RDP9 PDS database. Representative sequences were classiﬁed at 0.8 conﬁdence
threshold (Mothur v1.25.0 wang function)62. FastTree63 in nucleotide mode and
Mothurs align.seq function64 were used to construct a phylogenetic tree. Align-
ments were built with reference to the 2013 version of Greengenes65.
Statistics and data analysis. All data analysis was performed in the statistical
software package R version 3.3.0, with the package phyloseq66 to handle the
microbiome data. The Shannon diversity index and the Chao1 index were used as
measures of the within individual diversity (α-diversity), and the between indivi-
dual diversity metrics (β-diversity) were computed as weighted UniFrac67 distances
after adding a pseudocount (+1) to all OTU counts and log-transforming the OTU
tables. For sensitivity analyses unweighted UniFrac and Jensen–Shannon diver-
gence were used as other metrics of β-diversity. Differences in α-diversity between
groups were compared using Wilcoxon rank-sum test and differences in β-diversity
were visualized with principal coordinates analysis (PCoA) plots, in which the
PCoA ordinations were calculated based on all the samples visualized in the speciﬁc
plot and subsequently stratiﬁed. β-diversity was tested for inference using per-
mutational multivariate analysis of variance (PERMANOVA) (Adonis from the
package vegan with 999 permutations)68,69. In the interaction analyses, we included
an interaction term (e.g., asthma * asthma_status_mother). Differences in relative
abundances at the genus level were analyzed using Wilcoxon rank-sum (2 levels) or
Kruskal–Wallis Test (>2 levels). We used sparse partial least squares (PLS)70
modeling of asthma at age 5 years after ﬁltering genera (prevalence >5% of chil-
dren, >0.01% mean relative abundance) and log-transforming relative abundances,
using half the lowest nonzero value as a pseudocount. We selected the optimum
number of input variables using repeated 10-fold cross-validation of the area under
the curve (AUC) statistic to avoid overﬁtting. The ﬁnal model was chosen by the
highest median AUC value. The predicted values of left out folds were combined to
a PLS score. Loading of each genus in the model was in the ﬁgure drawn with
standard deviations across repeats as error bars, ranked by relative abundance and
colored by phylum. Clustering analysis was performed using partitioning around
medoids (PAM) clustering31 from the package cluster32. The Silhouette index71
calculated from weighted UniFrac distances was used for determining the optimal
number of clusters in the data. Indicator OTUs were identiﬁed using the function
multipatt from the package indicspecies72. Microbiota-by-age z-scores (MAZ)7
were calculated with non-asthmatics serving as the training set, with calculation of:
microbial maturity (MM) = (predicted microbiota age −median microbiota age);
and MAZ = (MM/SD) of predicted microbiota age as metrics. Associations between
PAM clusters and MAZ and asthma were assessed by Kaplan–Meier analyses and
quantiﬁed by Cox proportional hazards regression (P-values correspond to Wald
tests). The children were retained in the analysis from birth until age of asthma
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diagnosis, drop-out, or age 5 years, whichever came ﬁrst. Children with an asthma
diagnosis before sampling was excluded. The heatmap was constructed using the
package “pheatmap” and illustrates Spearman correlations between taxa, ﬁltered by
>10% genus presence and >10−3 mean relative abundance. Number of episodes of
troublesome lung symptoms was analyzed by a generalized estimating equation
Poisson regression model. Covariate analyses were conducted using χ2 tests for
categorical variables and t-tests or Wilcoxon rank-sum test for continuous vari-
ables. A signiﬁcance level of 0.05 was used in all analyses.
Data availability. The 16S sequences have been deposited in the Sequence Read
Archive (SRA) repository with the accession number PRJNA417357. All other
relevant data are available from the authors upon reasonable requests.
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